![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 23, 2024
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
November 25, 2024
EA5162 is testing a new therapy for certain patients with advanced NSCLC who have developed resistance to other treatments
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
September 17, 2024
A conversation with study chair James M. Ford, MD
September 17, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments
July 3, 2024
The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
June 13, 2024
This randomized phase 3 trial is comparing treatment with chemotherapy alone or with immunotherapy
April 11, 2024
This phase 2 imaging biomarker trial is evaluating whether novel biomarkers can accurately identify which patients will have better vs. worse survival outcomes early in their disease course
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone